Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats

Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1223-30. doi: 10.1016/j.numecd.2013.01.005. Epub 2013 Apr 30.

Abstract

Background and aims: The influence of lifestyle is well documented, especially the diet regime, in the development of type 2 diabetes (T2D) and associated cardiovascular diseases. Diabetic patients have increased risk of suffering cardiac ischemia and impaired response to such accidents. Methylglyoxal (MG) circulates at high concentration in diabetics' blood and is linked to the development of diabetes chronic complications. We propose that besides promoting the cardiovascular disease, MG may also negatively regulate the endogenous cardioprotection pathways after ischemia.

Methods and results: We performed a comparative study between three animal groups: normal Wistar (W), type 2 diabetic non-obese Goto-Kakizaki (GK) and normal rats submitted to MG chronic administration (3 months) with gradually enhanced concentration, up to 75 mg/Kg (WMG). Hearts were submitted to different experimental conditions: control, ischemia and ischemia-reperfusion. Levels of oxidative stress markers, advanced glycation end-products (AGEs) and their receptors (RAGEs) were evaluated. The serine/threonine protein kinase Akt (Akt), crucial for cardiomyocytes recovery after ischemia, and apoptosis markers were also assessed. Levels of MG, systemic and cardiac oxidative stress markers, AGEs and RAGEs were similar in GK and WMG groups. Akt protein was negatively regulated by MG, leading to impaired apoptotic markers.

Conclusion: Chronic MG administration to normal rodents mimicked most diabetic alterations, being associated with the development of cardiovascular disease and the impairment of survival pathways. Our results demonstrate the negative effect of MG rich diet in healthy animals and suggest the potential of methylglyoxal as a therapeutic target in diabetes.

Keywords: Cardiac ischemia; Hyperglycemia; Methylglyoxal; Type 2 diabetes.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Glycation End Products, Advanced / metabolism
  • Heart / drug effects*
  • Heart / physiopathology
  • Male
  • Myocardial Ischemia / chemically induced*
  • Oxidative Stress / drug effects
  • Pyruvaldehyde / administration & dosage
  • Pyruvaldehyde / adverse effects*
  • Rats
  • Rats, Wistar

Substances

  • Glycation End Products, Advanced
  • Pyruvaldehyde